Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD reduced its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 42.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 32,105 shares of the biotechnology company’s stock after selling 23,517 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.05% of Aldeyra Therapeutics worth $161,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ALDX. Barclays PLC lifted its position in shares of Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after buying an additional 48,313 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 2,822 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth about $69,000. AlphaCentric Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth about $234,000. Finally, Boston Financial Mangement LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth about $141,000. 59.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Aldeyra Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This trade represents a 36.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 9.60% of the stock is owned by corporate insiders.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $2.16 on Friday. The stock has a market cap of $129.38 million, a price-to-earnings ratio of -2.23 and a beta of 0.92. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The company’s 50-day moving average price is $3.56 and its two-hundred day moving average price is $4.73. Aldeyra Therapeutics, Inc has a 52 week low of $1.14 and a 52 week high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08. On average, analysts expect that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, April 4th. BTIG Research dropped their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, April 7th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.